Your browser doesn't support javascript.
loading
Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine.
Lassaunière, Ria; Polacek, Charlotta; Frische, Anders; Boding, Lasse; Sækmose, Susanne Gjørup; Rasmussen, Morten; Fomsgaard, Anders.
Afiliação
  • Lassaunière R; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
  • Polacek C; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
  • Frische A; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
  • Boding L; Danish National Biobank, Statens Serum Institut, Copenhagen, Denmark.
  • Sækmose SG; Department of Clinical Immunology, Zealand University Hospital, Naestved, Denmark.
  • Rasmussen M; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
  • Fomsgaard A; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
JAMA Netw Open ; 5(5): e2212073, 2022 05 02.
Article em En | MEDLINE | ID: mdl-35560054
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article